Patients affected by Eosinophilic Granulomatosis with Polyangiitis (EGPA) display an increased risk of atherothrombotic events compared with the general population. An increased frequency of subclinical markers of atherosclerosis has been observed in other anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), but no specific study focused on EGPA. We therefore evaluated subclinical atherosclerosis in EGPA patients and in a control population.
Evidence of subclinical atherosclerosis in Eosinophilic Granulomatosis with Polyangiitis (EGPA) / Bello, Federica; Bettiol, Alessandra; Silvestri, Elena; Mattioli, Irene; Urban, Maria Letizia; Palermo, Adalgisa; Mazzetti, Matteo; Malandrino, Danilo; Calcaterra, Ilenia; Vaglio, Augusto; Di Minno, Matteo Nicola Dario; Emmi, Giacomo; Prisco, Domenico. - In: RHEUMATOLOGY. - ISSN 1462-0324. - ELETTRONICO. - (2022), pp. ---. [10.1093/rheumatology/keac427]
Evidence of subclinical atherosclerosis in Eosinophilic Granulomatosis with Polyangiitis (EGPA)
Bello, Federica;Bettiol, Alessandra;Silvestri, Elena;Mattioli, Irene;Urban, Maria Letizia;Palermo, Adalgisa;Mazzetti, Matteo;Malandrino, Danilo;Vaglio, Augusto;Emmi, Giacomo;Prisco, Domenico
2022
Abstract
Patients affected by Eosinophilic Granulomatosis with Polyangiitis (EGPA) display an increased risk of atherothrombotic events compared with the general population. An increased frequency of subclinical markers of atherosclerosis has been observed in other anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), but no specific study focused on EGPA. We therefore evaluated subclinical atherosclerosis in EGPA patients and in a control population.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
